[Selpercatinib (advanced NSCLC with RET fusion) - Benefit assessment according to § 35a SGB V]

Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen
Record ID 32018004348
German
Original Title: Selpercatinib (RET-Fusions-positives NSCLC, Erstlinie)
Details
Project Status: Completed
Year Published: 2022
English language abstract: There is no English language summary available
Publication Type: Full HTA
Country: Germany
MeSH Terms
  • Carcinoma, Non-Small-Cell Lung
  • Lung Neoplasms
  • Protein Kinase Inhibitors
  • Pyrazoles
  • Pyridines
  • Antineoplastic Agents
Keywords
  • Selpercatinib
  • Carcinoma - Non-Small-Cell Lung
  • Benefit Assessment
Contact
Organisation Name: Institute for Quality and Efficiency in Health Care (IQWiG)
Contact Address: IQWiG, Siegburger Str. 237, 50679 Cologne, GERMANY, Tel: +49(0)221-35685, Fax: +49(0)221-356851
Contact Email: berichte@iqwig.de
Copyright: Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.